Matches in Wikidata for { <http://www.wikidata.org/entity/Q91488708> ?p ?o ?g. }
Showing items 1 to 39 of
39
with 100 items per page.
- Q91488708 description "artículu científicu espublizáu n'ochobre de 2018" @default.
- Q91488708 description "scientific article published on 01 October 2018" @default.
- Q91488708 description "wetenschappelijk artikel" @default.
- Q91488708 description "наукова стаття, опублікована в жовтні 2018" @default.
- Q91488708 name "Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line" @default.
- Q91488708 name "Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line" @default.
- Q91488708 type Item @default.
- Q91488708 label "Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line" @default.
- Q91488708 label "Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line" @default.
- Q91488708 prefLabel "Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line" @default.
- Q91488708 prefLabel "Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line" @default.
- Q91488708 P1433 Q91488708-7C37A101-B645-4918-B8DE-2455A19862AF @default.
- Q91488708 P1476 Q91488708-06675C64-957D-48AA-9B90-F07D856B9ABE @default.
- Q91488708 P2093 Q91488708-9F6B1F94-75F9-4C1F-BC4F-A594B2B80E7B @default.
- Q91488708 P304 Q91488708-4760127B-8F30-4CAA-8DAB-197B1509F3AA @default.
- Q91488708 P31 Q91488708-E186497A-873B-4F2C-8A42-28589A853BF6 @default.
- Q91488708 P356 Q91488708-CC2E2676-5430-428C-9474-20243B13A1A2 @default.
- Q91488708 P433 Q91488708-CF55BDD1-2926-4CE7-A48A-6058F0BEC06D @default.
- Q91488708 P478 Q91488708-A9F664A9-CEA9-4490-840E-EDC3F547BE76 @default.
- Q91488708 P577 Q91488708-188A8513-BB7B-41D4-BF99-66AD7D6DD3B3 @default.
- Q91488708 P698 Q91488708-29ABF9DF-2F1D-4AE6-B29C-CBE55A07FB31 @default.
- Q91488708 P921 Q91488708-A52EB8E0-A084-45C2-AF63-7E99426BD3C5 @default.
- Q91488708 P921 Q91488708-E50C3356-8836-4DC9-80B1-CB858D661C37 @default.
- Q91488708 P921 Q91488708-F70ED740-6BC9-456B-9E00-129E2D589CBF @default.
- Q91488708 P356 14737140.2018.1513792 @default.
- Q91488708 P698 30223694 @default.
- Q91488708 P1433 Q2999044 @default.
- Q91488708 P1476 "Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line" @default.
- Q91488708 P2093 "Nicoletta Colombo" @default.
- Q91488708 P304 "13-17" @default.
- Q91488708 P31 Q13442814 @default.
- Q91488708 P356 "10.1080/14737140.2018.1513792" @default.
- Q91488708 P433 "sup1" @default.
- Q91488708 P478 "18" @default.
- Q91488708 P577 "2018-10-01T00:00:00Z" @default.
- Q91488708 P698 "30223694" @default.
- Q91488708 P921 Q172341 @default.
- Q91488708 P921 Q18936 @default.
- Q91488708 P921 Q413299 @default.